Wilson J R, St John Sutton M, Schwartz J S, Ferraro N, Reichek N
Am J Cardiol. 1983 Aug;52(3):299-303. doi: 10.1016/0002-9149(83)90127-3.
To determine whether the circulatory response to hydralazine in heart failure is influenced by initial hemodynamic status or left ventricular (LV) chamber size, 28 patients with chronic LV dysfunction were studied. Hemodynamic measurements and echocardiographic LV end-diastolic dimension were correlated with the response to 20 mg of intravenous hydralazine and to a dose titrated in each patient to reduce systemic resistance by greater than or equal to 20%. Hydralazine, 20 mg, decreased systemic resistance from 23 +/- 8 to 18 +/- 8 U (p less than 0.01) and increased the cardiac index from 2.0 +/- 0.5 to 2.5 +/- 0.6 liters/min/m2 (p less than 0.01) and the stroke work index from 21 +/- 11 to 24 +/- 9 g . m/m2 (p less than 0.05). Titrating the dose to decrease systemic resistance by greater than or equal to 20% increased the cardiac index further to 2.7 +/- 0.6 liters/min/m2 and the stroke work index to 32 +/- 9 g . m/m2. The change in systemic resistance produced by 20 mg of hydralazine correlated only with initial systemic resistance (r = 0.53), suggesting that vascular response to hydralazine is a direct function of initial vascular resistance. The percentage change in stroke work index produced by 20 mg of hydralazine correlated directly with indexes of LV preload-end-diastolic wall stress (r = 0.69) and pulmonary wedge pressure (r = 0.43) and inversely with stroke work index (r = -0.49), an index of ventricular work. Similar but less close correlations were observed when the dose of hydralazine was titrated. The hemodynamic response to hydralazine did not correlate with LV end-diastolic dimension or right atrial pressure. Thus, vascular response to moderate doses of hydralazine is related to initial systemic vascular resistance. LV pump response is related to the level of initial LV pump dysfunction but not to LV chamber size or right atrial pressure.
为了确定心力衰竭患者对肼屈嗪的循环反应是否受初始血流动力学状态或左心室(LV)腔大小的影响,对28例慢性左心室功能不全患者进行了研究。血流动力学测量和超声心动图测定的左心室舒张末期内径与对20mg静脉注射肼屈嗪的反应以及根据每位患者的情况滴定剂量以降低全身阻力≥20%的反应相关。20mg肼屈嗪使全身阻力从23±8U降至18±8U(p<0.01),使心脏指数从2.0±0.5升/分钟/平方米增至2.5±0.6升/分钟/平方米(p<0.01),使每搏作功指数从21±11g·m/平方米增至24±9g·m/平方米(p<0.05)。滴定剂量以降低全身阻力≥20%可使心脏指数进一步增至2.7±0.6升/分钟/平方米,每搏作功指数增至32±9g·m/平方米。20mg肼屈嗪引起的全身阻力变化仅与初始全身阻力相关(r = 0.53),提示对肼屈嗪的血管反应是初始血管阻力的直接函数。20mg肼屈嗪引起的每搏作功指数百分比变化与左心室前负荷-舒张末期壁应力指数(r = 0.69)和肺楔压(r = 0.43)直接相关,与心室作功指数每搏作功指数(r = -0.49)呈负相关。滴定肼屈嗪剂量时观察到类似但不太密切的相关性。对肼屈嗪的血流动力学反应与左心室舒张末期内径或右心房压力无关。因此,对中等剂量肼屈嗪的血管反应与初始全身血管阻力有关。左心室泵反应与初始左心室泵功能障碍的程度有关,但与左心室腔大小或右心房压力无关。